ロード中...
Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Alternative Sunitinib Schedules
PURPOSE: To identify sunitinib alternative schedules (AS) that maintained dose intensity while decreasing adverse events (AEs) in patients with metastatic renal cell cancer (mRCC), and to determine impact of AS on clinical outcomes. PATIENTS AND METHODS: A retrospective review of patients ≥ 18 yr of...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4015627/ https://ncbi.nlm.nih.gov/pubmed/24018239 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.juro.2013.08.090 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|